Biomarin Pharmaceutical (BMRN) Operating Expenses (2009 - 2026)

Biomarin Pharmaceutical has disclosed Operating Expenses across 18 years of filings, most recently posting $636.6 million for Q1 2026.

• Quarterly Operating Expenses rose 22.12% year-over-year to $636.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.9 billion (up 25.59% YoY) and the FY2025 annual result came in at $2.8 billion, up 18.66% from the prior year.
• Operating Expenses slipped to $636.6 million in Q1 2026, from $919.2 million in the prior quarter.
• Over five years, Operating Expenses peaked at $919.2 million in Q4 2025 and troughed at $382.0 million in Q1 2022.
• A 5-year average of $587.4 million and a median of $550.8 million in 2023 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2022 — Operating Expenses declined 17.12% — and 2025, when it jumped 56.88%.
• Tracing BMRN's Operating Expenses over 5 years: stood at $550.6 million in 2022, then advanced by 12.4% to $618.9 million in 2023, then declined by 5.34% to $585.9 million in 2024, then soared by 56.88% to $919.2 million in 2025, then tumbled by 30.75% to $636.6 million in 2026.
• Business Quant data shows BMRN's Operating Expenses at $636.6 million in Q1 2026, $919.2 million in Q4 2025, and $822.8 million in Q3 2025.